TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04220190: Phase 2/3 Trial of Autologous Hybrid TREG/Th2 (RAPA-501) T Stem Cell Therapy for Amyotrophic Lateral Sclerosis

Sponsor: Rapa Therapeutics LLC · Phase: PHASE2/PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 41 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,105,600

Rescue Site Savings

+$13,257,130

Unlock Full NCT04220190 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04220190 Rescue Dossier →